Picrotoxinin comes from the seeds of Anamirta cocculus, a plant found in parts of Southeast Asia and India. Credit: iStock

Taming a plant-derived toxin

Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments.

December 20, 2023


LA JOLLA, CA—Picrotoxinin, a plant-derived toxin that Asian fishermen traditionally have used to paralyze and catch fish, has long been seen as a possible starting point for new human therapeutics and other neuroactive products. Yet little progress has been made, due to picrotoxinin’s chemical instability and toxicity, along with the difficulty of making and modifying its complex structure. Now, however, chemists at Scripps Research have found a relatively easy way to make versions of picrotoxinin with improved properties.

In a study published in Nature Communications on December 14, 2023, the researchers showed that close chemical variants of picrotoxinin that contain a single small modification have better chemical stability, are much easier to make and modify, and are safer for humans. This opens the door to developing new neurological drugs, safer pesticides and even anti-parasite treatments. 

“Just a small alteration to the natural product gives it properties that have been elusive for decades,” says study senior author Ryan Shenvi, PhD, a professor in the Department of Chemistry at Scripps Research.

The first author was Guanghu Tong, PhD, a postdoctoral research associate in the Shenvi Lab during the study.

Picrotoxinin comes from the seeds—often called “fishberry” seeds because of their use by fishermen—of Anamirta cocculus, a plant found in parts of Southeast Asia and India. The toxin potently blocks the activity of neuronal receptors found in most higher organisms. In mammals, these are called GABAA receptors, and they exist throughout the brain, largely to prevent other neurons from becoming overactive. Even at small doses, picrotoxinin’s blocking of these receptors can cause seizures and fatally disrupt the nerve signals that control breathing.

It might seem contradictory that chemists would turn to poisons for making new medicines, but many plant toxins, in addition to hitting desirable targets, already have good drug-like properties such as the ability to get to their targets via oral dosing. In the case of picrotoxinin, chemists would like to modify it to develop drugs for psychiatric and neurological disorders, safe and effective pesticides and anti-parasite drugs, and laboratory tools to precisely manipulate GABAA receptors. The problem has been that picrotoxinin’s other chemical properties, such as its synthetic difficulty and tendency to react with ordinary solvents, have made it extraordinarily hard to tame.

Shenvi’s lab specializes in using organic chemistry techniques to overcome such challenges and find ways to improve natural products. For years, he and his team have been focusing on molecules that target GABAA receptors, and in 2020, they reported the shortest-ever organic synthesis of picrotoxinin.

In that study, they found they could much more easily synthesize a compound that was almost the same as picrotoxinin. 5Me-picrotoxinin, as they called it, could still bind to GABAA receptors, and only differed from its chemical cousin by the addition of a cluster of atoms—called a methyl group—at a key position on the molecule. For the new study, Shenvi's team investigated 5Me-picrotoxinin’s novel properties, given this one structural change.

The team synthesized two parallel sets of picrotoxinin and 5Me-picrotoxinin variants, determining how the absence or presence of the methyl group changes the molecule’s stability and receptor binding selectivity. They discovered that the methylated version is chemically much more stable, with a bloodstream half-life that seems to be nearly triple that of ordinary picrotoxinin. They also found that 5Me-picrotoxinin is much less prone to reactions with common solvents including alcohols and acids. Co-authors Shuming Chen, PhD, assistant professor of chemistry at Oberlin College, and her lab member Anna Crowell, explained this using computational modeling.

Another surprise was that the methylated version has lower potency against mammalian GABAA receptors while retaining high potency against insect versions of the receptor—just what one would want for a safe insect-killing compound. 

“The fact that picrotoxinin targets a family of receptors including GABAA receptors has been known for several decades, but this is the first time we’ve been able to change its selectivity for those receptors,” Tong says. 

The experiments with picrotoxinin variants and insect receptors were conducted by collaborating researchers at Corteva Agriscience, developers of pest-control products. Models built for the study by Corteva computational chemist Avery Sader, PhD, suggest further ways to modify 5Me-picrotoxinin to make it more selective for insect pests and thus safer for humans.

The researchers plan to continue synthesizing and investigating new variants of 5Me-picrotoxinin for their potential to be developed into new medicines and other products.

“C5 Methylation Confers Accessibility, Stability and Selectivity to Picrotoxinin” was co-authored by Guanghu Tong, Samantha Griffin, Avery Sader, Anna Crowell, Ken Beavers, Jerry Watson, Zachary Buchan, Shuming Chen and Ryan Shenvi.

Support for the research was provided by the National Institutes of Health (R35 GM122606) and Jiangsu Industrial Technology Research Institute.


For more information, contact press@scripps.edu See More News